SI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN), a leader in treating musculoskeletal disorders, will announce its second-quarter 2022 financial results on August 8, 2022, post-market. A live conference call will follow at 1:30 PM PT/4:30 PM ET, accessible by phone or via webcast on their website. The company, known for its iFuse Implant System, has established a robust market presence with over 65,000 procedures performed. Their proprietary reimbursement advantage underscores their market leadership in surgical treatments for sacropelvic issues.

Positive

• Established coverage for SI joint fusion procedures with iFuse Implant System by multiple payors
• Over 65,000 SI joint fusion procedures performed by more than 2,700 surgeons

Negative

• None.

SANTA CLARA, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2022 after market close on Monday, August 8, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (888) 346-8835 for domestic callers or (412) 902-6646 for international callers and asking the operator to join the SI-BONE call. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,700 surgeons have performed a combined total of more than 65,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT’s and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

When will SI-BONE report its second-quarter 2022 financial results?

SI-BONE will report its second-quarter financial results after market close on August 8, 2022.

How can I listen to the SI-BONE conference call?

Investors can listen to the SI-BONE conference call by dialing (888) 346-8835 for domestic calls or (412) 902-6646 for international calls.

What is the iFuse Implant System?

The iFuse Implant System is a minimally invasive surgical technology for treating SI joint disorders, with over 65,000 successful procedures performed.

Who can access the webcast of the financial results?

The webcast of the financial results will be available on the Investors section of SI-BONE's website and archived for at least 90 days.